AI Article Synopsis

  • Accurate treatment response assessment using serial CT scans is crucial for cancer clinical trials, but the current method (RECIST guideline) can be subjective and imprecise, especially for multifocal liver cancer lesions.
  • The newly developed RECORD system utilizes deep learning to objectively evaluate treatment responses, segment liver tumors, and provide classifications based on tumor volume analysis, achieving high accuracy in assessments across multiple studies.
  • RECORD outperforms traditional methods by correlating strongly with clinical evaluations and effectively stratifying patient risks, suggesting a need for future research to apply this technology to other types of cancer.

Article Abstract

Accurate treatment response assessment using serial CT scans is essential in oncological clinical trials. However, oncologists' assessment following the Response Evaluation Criteria in Solid Tumors (RECIST) guideline is subjective, time-consuming, and sometimes fallible. Advanced liver cancer often presents multifocal hepatic lesions on CT imaging, making accurate characterization more challenging than with other malignancies. In this work, we developed a tumor volume guided comprehensive objective response evaluation based on deep learning (RECORD) for liver cancer. RECORD performs liver tumor segmentation, followed by sum of the volume (SOV)-based treatment response classification and new lesion assessment. Then, it can provide treatment evaluations of response, stability, and progression, and calculates progression-free survival (PFS) and response time. The RECORD pipeline was developed with both CNN and ViT backbones. Its performance was evaluated in three longitudinal cohorts involving 60 multi-national centers, 206 patients, 891 CT scans, using internal five-fold cross-validation and external validations. RECORD with the most effective backbone achieved an average AUC-response of 0.981, AUC-stable of 0.929, and AUC-progression of 0.969 for SOV-based disease status classification, F1-score of 0.887 for new lesion identification, and accuracy of 0.889 for final treatment outcome assessments across all cohorts. RECORD's PFS and response time predictions strongly correlated with clinician's assessments (P < 0.001). Moreover, RECORD can better stratify high-risk versus low-risk patients for overall survival compared to the human-assessed RECIST results. In conclusion, RECORD demonstrates efficiency and objectivity in analyzing liver lesions for treatment response evaluation. Further research should extend the pipeline to other metastatic organ sites.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11570623PMC
http://dx.doi.org/10.1038/s41698-024-00754-zDOI Listing

Publication Analysis

Top Keywords

liver cancer
12
deep learning
8
treatment response
8
response evaluation
8
pfs response
8
response time
8
response
7
treatment
5
learning oncologic
4
oncologic treatment
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!